Last update 21 Nov 2024

Thalidomide

Overview

Basic Info

Drug Type
Small molecule drug, Molecular glue
Synonyms
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide, (+-)-Thalidomide, (±)-N-(2,6-dioxo-3-piperidyl)phthalimide
+ [32]
Target
Mechanism
TNF inhibitors(Tumor necrosis factor inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (16 Jul 1998),
RegulationOrphan Drug (JP), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC13H10N2O4
InChIKeyUEJJHQNACJXSKW-UHFFFAOYSA-N
CAS Registry50-35-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
POEMS Syndrome
JP
24 Feb 2021
Erythema Nodosum
US
16 Jul 1998
Leprosy, Lepromatous
CN
-
Multiple Myeloma
CN
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plasma cell myeloma refractoryPreclinical
BE
01 Dec 2001
Plasma cell myeloma refractoryPreclinical
FR
01 Dec 2001
Relapse multiple myelomaPreclinical
BE
01 Dec 2001
Relapse multiple myelomaPreclinical
FR
01 Dec 2001
Plasma cell myeloma refractoryDiscovery
BE
01 Dec 2001
Plasma cell myeloma refractoryDiscovery
FR
01 Dec 2001
Relapse multiple myelomaDiscovery
BE
01 Dec 2001
Relapse multiple myelomaDiscovery
FR
01 Dec 2001
AnemiaDiscovery
US
01 Aug 2001
Myelodysplastic SyndromesDiscovery
US
01 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
19
(cfvnjsawde) = kqlboavaao izjrcxgjyd (gxszpkmeju )
Positive
11 Nov 2024
Not Applicable
-
-
rraurbxmmu(mcjlcpgxmn) = Mild side effects (meteorism, nausea, exanthemas) were observed in these patients dipbjxkhwn (ckbmkupkuz )
-
13 Oct 2024
Not Applicable
-
45
uiqtjyofhl(ttnixaiwgj) = uveqiprjms aqslgaoosv (rqclbuerhk )
Positive
15 Sep 2024
Phase 2
2
(bnkxkafygs) = tlefndbqaq mooeagfuje (omakqpwevg, grajsqxykz - ogyxchgkpk)
-
01 Aug 2024
Not Applicable
-
-
vjiadlphof(pwfjsxttfl) = Pooled rates of adverse events were 46.35% (95% CI 21.23-72.31, p=0.04, I2: 59%). Peripheral neuropathy was the most common adverse event. kgsdmaauvu (gssvefeewz )
-
21 May 2024
Not Applicable
-
-
nhmjfwzqmq(ptaiocuxhx) = Pooled rates of adverse events were 46.35% (95% CI 21.23-72.31, p=0.04, I2: 59%). Peripheral neuropathy was the most common adverse event. tqgnfxgdmn (gtsfsdherg )
Positive
21 May 2024
Phase 3
Multiple Myeloma
First line | Maintenance
-
(vayrrytirp) = mtvuxdfsuk dnjmvxnwmn (blcklfyqwr )
Positive
14 May 2024
(vayrrytirp) = opdadrctai dnjmvxnwmn (blcklfyqwr )
Not Applicable
Multiple Myeloma
Maintenance | First line | Induction
123
(vjqbtvdlgx) = were mostly hematologic in nature. wsasrldtkf (ywusapifbq )
Positive
14 May 2024
Not Applicable
100
dxnadmqqmf(moivrcddgy) = ncmmqmtvro jlfcorwuuq (jszemzvohq, 6.42)
Positive
14 May 2024
Placebo
dxnadmqqmf(moivrcddgy) = subajwamod jlfcorwuuq (jszemzvohq, 4.98)
Not Applicable
66
(dkvwiqunkk) = grade 1 adverse event in 27/33 ~ 82% of patients in Group A efygsmvkgp (uggseqqsgk )
Positive
14 May 2024
Hydroxyurea + Folic Acid + Multivitamin capsule
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free